Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Radford

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Current knowledge and future research directions in treatment-related second primary malignanciesLindsay M Morton, Anthony J Swerdlow, Michael Schaapveld, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaAlexander Spira, Xiaolei Zhou, Lei Chen, et al.
The Journal of Molecular Diagnostics : JMD|March 27, 2012
Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphomaKim Linton, Christopher Howarth, Mark Wappett, et al.
Plos One|April 3, 2020
Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trialThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Plos One|March 28, 2023
Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutionsThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Acta Oncologica (Stockholm, Sweden)|August 27, 2025
Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000Hannah Chamberlin, Georgios Ntentas, David J Cutter, et al.
Future Oncology (London, England)|November 12, 2024
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 studyMehdi Hamadani, Paolo F Caimi, Brian Hess, et al.
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Current knowledge and future research directions in treatment-related second primary malignanciesLindsay M Morton, Anthony J Swerdlow, Michael Schaapveld, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaAlexander Spira, Xiaolei Zhou, Lei Chen, et al.
The Journal of Molecular Diagnostics : JMD|March 27, 2012
Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphomaKim Linton, Christopher Howarth, Mark Wappett, et al.
Plos One|April 3, 2020
Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trialThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Plos One|March 28, 2023
Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutionsThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Acta Oncologica (Stockholm, Sweden)|August 27, 2025
Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000Hannah Chamberlin, Georgios Ntentas, David J Cutter, et al.
Future Oncology (London, England)|November 12, 2024
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 studyMehdi Hamadani, Paolo F Caimi, Brian Hess, et al.
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Pageof 11